株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

PharmaPoint:大うつ病性障害 - 日本における医薬品の予測と市場分析

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023

発行 GlobalData 商品コード 305472
出版日 ページ情報 英文 136 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: GlobalData社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
PharmaPoint:大うつ病性障害 - 日本における医薬品の予測と市場分析 PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023
出版日: 2014年05月30日 ページ情報: 英文 136 Pages
概要

大うつ病性障害は、世界で最も一般的な精神疾患の一つです。同市場は競合が激しく、30を超える製品が治療薬として上市されています。主要製品の特許切れや、最終段階のパイプライン製品の市場投入を目前に、市場は大きく動いています。日本ではBrintellixおよび最終段階にあるパイプライン製品7種が市場に投入されると見込まれており、その他Cymbalta、Lexaproの売り上げが合わせて1億6200万米ドルに達すると予測されています

当レポートでは、日本における大うつ病性障害の治療薬市場について調査分析し、疾患の概要とガイドライン、競合情勢、主要薬剤の詳細情報(製品説明、安全性、有効性)、SWOT分析、売上高予測、影響分析(動向、促進要因・抑制要因)などをまとめ、お届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾患の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 分類
  • 症状およびサブタイプ
  • 予後
  • QOL

第4章 疾病の管理

  • 症状と治療の概要
  • 日本

第5章 競合評価

  • 概要
  • 製品プロファイル:主要ブランド、選択的セロトニン再取り込み阻害剤
  • 製品プロファイル:主要ブランド、セロトニン-ノルアドレナリン再取り込み阻害剤
  • 製品プロファイル:主要ブランド、その他の抗うつ薬
  • 製品プロファイル:主要ブランド、抗精神薬
  • その他の治療薬クラス

第6章 機会とアンメットニーズ

  • 概要
  • より効果的な薬物療法
  • より良好な副作用プロファイル
  • 抗うつ効果の迅速な発現
  • 個別化医療のアプローチ

第7章 パイプライン評価

  • 概要
  • 臨床開発中の有望な薬剤
  • その他開発中の薬剤

第8章 市場の見通し

  • 日本

第9章 付録

図表

目次
Product Code: GDHC244CFR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded and competitive market, with more than 30 marketed products available for the treatment of patients with MDD. The depression market is about to enter a dynamic phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.

The anticipated growth of the depression market in Japan is due to the expected launch of Brintellix and the potential introduction of seven late-stage pipeline products into the market during the forecast period. GlobalData anticipates Elli Lilly's Cymbalta and Lundbeck/Forest (Actavis)/Mitsubishi Tanabe Pharma/Mochida's Lexapro to be the top-selling products by the end of the forecast period in Japan, generating combined sales of approximately $162.2m.

Scope

  • Overview of Major depressive disorder including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Japan from 2013-2023.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Japan Major depressive disorder market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Major depressive disorder.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2013-2023 in Japan.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Classification
  • 3.3. Symptoms and Subtypes of Major Depressive Disorder
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. Japan

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles: Major Brands, Selective Serotonin Reuptake Inhibitors
    • 5.2.1. Lexapro (Escitalopram)
    • 5.2.2. Other Selective Serotonin Reuptake Inhibitors
  • 5.3. Product Profiles: Major Brands, Serotonin-Norepinephrine Reuptake Inhibitors
    • 5.3.1. Cymbalta (Duloxetine)
  • 5.4. Product Profiles: Major Brands, Other Antidepressants
    • 5.4.1. Noradrenaline and Specific Serotonergic Antidepressants
    • 5.4.2. Tricyclic Antidepressants
    • 5.4.3. Brintellix (Vortioxetine)
  • 5.5. Product Profiles: Major Brands, Antipsychotics
    • 5.5.1. Abilify (Aripiprazole)
    • 5.5.2. Seroquel XR (Quetiapine)
  • 5.6. Other Therapeutic Classes

6. Unmet Needs and Opportunities

  • 6.1. Overview
  • 6.2. More Effective Pharmacotherapies
    • 6.2.1. Unmet Needs
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunities
  • 6.3. More Favorable Side Effect Profiles
    • 6.3.1. Unmet Needs
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunities
  • 6.4. Rapid Onset of Antidepressant Effects
    • 6.4.1. Unmet Needs
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunities
  • 6.5. Personalized Treatment Approach
    • 6.5.1. Unmet Needs
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunities

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Brexpiprazole (OPC-34712)
    • 7.2.2. Cariprazine (RGH-188)
    • 7.2.3. ALKS-5461
    • 7.2.4. Amitifadine (EB-1010)
    • 7.2.5. GLYX-13
    • 7.2.6. Tedatioxetine (Lu AA24530)
    • 7.2.7. ETS6103
  • 7.3. Other Drugs in Development

8. Market Outlook

  • 8.1. Japan
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers - Global Issues
    • 8.1.4. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed MDD Patients
    • 9.4.2. Percent of Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in this Study
  • 9.6. About the Authors
    • 9.6.1. Analyst
    • 9.6.2. Therapy Area Directors
    • 9.6.3. Global Head of Healthcare
  • 9.7. About GlobalData
  • 9.8. Disclaimer

List of Tables

  • Table 1: Classification and Criteria of Major Depressive Disorder (DSM-IV) and Major Depressive Episode (ICD-10)
  • Table 2: Subtypes of Major Depressive Disorder
  • Table 3: Severity of Depressive Episodes according to ICD-10 and DSM-IV Diagnostic Criteria
  • Table 4: Treatment Guidelines for Major Depressive Disorder
  • Table 5: Most Prescribed Drugs for MDD by Class in Japan, 2013
  • Table 6: Country Profile - Japan
  • Table 7: Leading Treatments for MDD, 2013
  • Table 8: Product Profile - Lexapro
  • Table 9: Safety of Lexapro - Five Most Frequently Reported Adverse Events
  • Table 10: Lexapro SWOT Analysis, 2014
  • Table 11: Relative Frequency of Common Adverse Effects for Different SSRIs
  • Table 12: Product Profile - Cymbalta
  • Table 13: Cymbalta SWOT Analysis, 2023
  • Table 14: Product Profile - Mirtazapine
  • Table 15: Safety of Mirtazapine - Four Most Frequently Reported Adverse Events
  • Table 16: Mirtazapine SWOT Analysis, 2014
  • Table 17: TCAs SWOT Analysis, 2014
  • Table 18: Product Profile - Brintellix
  • Table 19: Efficacy of Brintellix in Six-Week to Eight-Week Clinical Trials
  • Table 20: Safety of Brintellix - Five Most Frequently Reported Adverse Events
  • Table 21: Brintellix SWOT Analysis, 2014
  • Table 22: Product Profile - Abilify
  • Table 23: Safety of Abilify - Five Most Frequently Reported Adverse Events
  • Table 24: Abilify SWOT Analysis, 2014
  • Table 25: Product Profile - Seroquel XR
  • Table 26: Efficacy of Seroquel XR as an Adjunctive Therapy to Antidepressants
  • Table 27: Safety of Seroquel XR- Five Most Frequently Reported Adverse Events
  • Table 28: Seroquel XR SWOT Analysis, 2014
  • Table 29: Summary of Minor Therapeutic Classes in MDD, 2013
  • Table 30: Unmet Needs and Opportunities in MDD
  • Table 31: Comparison of Therapeutic Classes in Development for MDD, 2013
  • Table 32: Product Profile - Brexpiprazole
  • Table 33: Safety of Brexpiprazole - Most Frequently Reported Adverse Events
  • Table 34: Brexpiprazole SWOT Analysis, 2014
  • Table 35: Product Profile - Cariprazine
  • Table 36: Cariprazine SWOT Analysis, 2014
  • Table 37: Product Profile - ALKS-5461
  • Table 38: ALKS-5461 SWOT Analysis, 2014
  • Table 39: Product Profile - Amitifadine
  • Table 40: Amitifadine SWOT Analysis, 2014
  • Table 41: Product Profile - GLYX-13
  • Table 42: GLYX-13 SWOT Analysis, 2014
  • Table 43: Product Profile - Tedatioxetine
  • Table 44: Tedatioxetine SWOT Analysis, 2014
  • Table 45: Product Profile - ETS6103
  • Table 46: ETS6103 SWOT Analysis, 2014
  • Table 47: Drugs in Development for MDD, 2014
  • Table 48: Sales Forecasts ($m) for MDD in Japan, 2013-2023
  • Table 49: Key Events Impacting Sales for MDD in Japan, 2013-2023
  • Table 50: MDD Market - Drivers and Barriers, 2013-2023
  • Table 51: MDD Market in Japan - Drivers and Barriers, 2013-2013
  • Table 52: Key Launch Dates
  • Table 53: Key Patent Expiries
  • Table 54: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons
  • Figure 2: Disease Management Model for Major Depressive Disorder
  • Figure 3: Major Depressive Disorder Treatment Algorithm
  • Figure 4: MDD - Phase IIb-III Pipeline, 2014
  • Figure 5: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2013-2023
  • Figure 6: Clinical and Commercial Positioning of Brexpiprazole
  • Figure 7: Clinical and Commercial Positioning of Cariprazine
  • Figure 8: Clinical and Commercial Positioning of ALKS-5461
  • Figure 9: Clinical and Commercial Positioning of Amitifadine
  • Figure 10: Clinical and Commercial Positioning of GLYX-13
  • Figure 11: Clinical and Commercial Positioning of Tedatioxetine
  • Figure 12: Clinical and Commercial Positioning of ETS6103
  • Figure 13: Sales for MDD in Japan by Drug Class, 2013-2023
Back to Top